Insilico Medicine Doses First Patient in GENESIS-IPF-3, the World's First Phase III Trial of a Generative AI-Driven Innovative Drug

Insilico Medicine announced that the first patient has been dosed with Rentosertib (ISM001-055/INS018_055) in the GENESIS-IPF-3 clinical trial. The milestone advances the company’s generative-AI-enabled drug-development pipeline, though the article excerpt provides no efficacy, safety, enrollment, or financial data.